However, vaccines containing conjugated or unconjugated MUC1 peptides, plus various adjuvants, failed to induce therapeutic tumor-specific CTLs in vivo [17], which may be due to protein conformational dissimilarities, improper vaccine formulations, and inadequate adjuvants [13, 15]. This evidence concerns the gene MUC1 and neoplasm.